Figure 1

Etanercept in active rheumatoid arthritis (TEMPO trial): ACR responses at 52 weeks. *P < 0.01, ^‡P < 0.0001, versus placebo; ^†P < 0.05, ^§P < 0.0001, versus etanercept. ACR, American College of Rheumatology; MTX, methotrexate; TEMPO, Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes. Reprinted with permission [16].